[Skip to Content]
Access to paid content on this site is currently suspended due to excessive activity being detected from your IP address 50.16.17.16. Please contact the publisher to request reinstatement.
[Skip to Content Landing]
JAMA Clinical Evidence Synopsis
February 20, 2013

Clinical Outcomes Associated With Procalcitonin Algorithms to Guide Antibiotic Therapy in Respiratory Tract Infections

Author Affiliations
 

JAMA Clinical Evidence Synopsis Section Editor: Mary McGrae McDermott, MD, Contributing Editor. We encourage authors to submit papers for consideration as a JAMA Clinical Evidence Synopsis. Please contact Dr McDermott at mdm608@northwestern.edu

Author Affiliations: Medical University Department, Kantonsspital Aarau, Tellstrasse, Aarau, Switzerland (Drs Schuetz and Mueller); Basel Institute for Clinical Epidemiology and Biostatistics, University Hospital Basel, Switzerland (Dr Briel); and Department of Clinical Epidemiology and Biostatistics, McMaster University, Hamilton, Ontario, Canada (Dr Briel).

JAMA. 2013;309(7):717-718. doi:10.1001/jama.2013.697
Abstract

Clinical Question In patients with respiratory tract infection, is measurement of procalcitonin to guide antibiotic prescriptions associated with reduced antibiotic exposure without increases in all-cause mortality or treatment failure?

Bottom Line The measurement of procalcitonin to guide initiation and duration of antibiotic treatment in patients with respiratory tract infections of varying severity is associated with lower antibiotic exposure without increasing all-cause mortality or treatment failure.

×